CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ... have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual ...

“This presentation reflects our focus on developing non-invasive, scalable diagnostics rooted in the promise of liquid biopsy innovation,” said Holly Magliochetti, CEO of PanGIA Biotech.

Presenter: Katharine Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center, and Principal Investigator of the VERSATILE-003 clinical ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual ...

today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of ...